Vollständiger Abstract
Worum geht es in dieser Arbeit?
In this update we review new evidence on the rising prevalence of prior authorization rejections, delays and denials affecting US patients seeking access to branded prescription medications. We also examine a comparative study of cost-effectiveness thresholds cited in the USA and in countries designated as comparators under the Most-Favored-Nations Executive Order.
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Sreeram V Ramagopalan, Annie Jullien Pannelay
- Quelle
- Journal of Comparative Effectiveness Research
- Publikation
- 2026-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 2042-6305, 2042-6313
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Sreeram V Ramagopalan, Annie Jullien Pannelay (2026). Access in all areas? A round-up of developments in market access and health technology assessment: part 16. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2026-0153